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presenting manifestation of long-standing severe
male hypogonadotropic hypogonadism: a case
series
Elena Passeri1, Marco Bonomi2, Francesco Dangelo3, Luca Persani4 and Sabrina Corbetta1*Abstract
Background: Physiological functioning of the testes is important for cardiac health besides for virilisation, physical
strength, behavior and reproduction; moreover, hypogonadism has been demonstrated as a significant risk marker
of increased all-cause and cardiovascular mortality.
Cases presentation: We reported two cases of long-standing hypogonadotropic hypogonadism presenting with
wasting, bradycardia and heart failure. The two patients were admitted to emergency department for deep
weakness, unresponsive anemia and severe bradycardia, requiring in one case the implanting of a monocameral
pace-maker for treatment of heart failure. No previous cardiologic disorders were known and cardiac ischemia was
ruled out in both patients. The first patient presented congenital hypogonadotropic hypogonadism combined with
mild central hypothyroidism and growth hormone deficiency occurred in the peripubertal age, while the second
one was diagnosed with isolated adult-onset severe central hypogonadism. Testosterone deficiency was the main
feature in both patients as physical examination revealed clinical stigmata of hypogonadism and testosterone
replacement induced a dramatic improvement of general condition. Genetic analysis of genes involved in
hypogonadotropic hypogonadism failed to identify alterations.
Conclusion: Long-standing hypogonadism in males can be associated with life threatening body alterations
including severe bradycardia and heart failure.
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Hypogonadotropic hypogonadism is defined as a clinical
syndrome that results from gonadal failure due to abnor-
mal pituitary gonadotropin levels, resulting from either
absent or inadequate hypothalamic gonadotropin releasing
hormone (GnRH) secretion or failure of pituitary gona-
dotropin secretion. The condition may be isolated as well
as in association with other pituitary hormone deficiency
states. Causes of hypogonadotropic hypogonadism may
be acquired, frequently due to structural lesions of the
hypothalamic-pituitary region, functional or congenital, as* Correspondence: sabrina.corbetta@unimi.it
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unless otherwise stated.a growing list of genes has been implicated in the molecu-
lar pathogenesis of hypogonadotropic hypogonadism.
Clinical presentation of hypogonadotropic hypogonadism
depends on the time of onset, as a prepubertal onset lead
to delayed sexual development, eunuchoidal proportions,
and cryptorchidism as well as the severity of the defect and
the presence of associated conditions. Besides infertility
and sexual impairment, androgen deficiency is associated
with a number of extra-gonadal metabolic changes like de-
cline in energy, depression, reduced muscle and bone mass
and increased abdominal fat [1]. Recently, low testosterone
levels have been demonstrated as a significant risk marker
of increased all-cause and cardiovascular mortality [2], sug-
gesting an emerging role of testosterone on cardiac health
in males. Low levels of testosterone have been found to beLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ure, where hypogonadism could play a role in favoring the
onset of some peculiar features like decreased exercise cap-
acity, diminished muscle mass and energy handling and
final cachexia [3]. However, isolated hypogonadism is rarely
associated with an acute onset with bradycardia and heart
failure [4], while hypopituitarism may be life-threatening,
especially when adrenocorticotropic hormone deficiency
occurs [5], and may present with cardiovascular events like
cardiac arrhythmia or congestive heart failure due to di-
lated cardiomyopathy [6,7].
Here we described two cases of severe long-standing
hypogonadotropic hypogonadism associated with acute
presentation in an emergency setting of bradycardia,
heart failure and wasting syndrome besides the classical
hypogonadal phenotype. The first patient presented
with multiple pituitary defects as severe hypogonado-
tropic hypogonadism was associated with mild central
hypothyroidism and growth hormone (GH) deficiency,
while the second patient was diagnosed as isolated
adult-onset severe central hypogonadism. In both pa-
tients, androgen deficiency was long-standing and oc-
curred in their very early adulthood.
Case presentation
Case 1
A 65 years-old male was admitted to emergency depart-
ment for heart failure due to severe bradycardia (27 bpm),
third degree atrioventricular block, mild hypokinetic
cardiomyopathy and anemia [hemoglobin 7.2 g/dl (n.v.
12.0-15.0)]. A monocameral pace-maker was successfully
implanted. No previous cardiologic disorders were known.
The patients presented lethargic and bed bound from few
days, but experienced progressive physical deterioration in
the last year. Consanguinity was absent and puberty oc-
curred at the expected age in siblings. At the age of
14 years he was diagnosed for delayed puberty due to iso-
lated hypogonadotropic hypogonadism. The patient was
treated with testosterone for few months, then he refused
all the therapeutic effort, in agreement with his parents,
and spent all his life without testosterone replacement.
His cognitive ability was normal, he completed his study
and worked as employed till he retired. Indeed, he lived
alone with poor socialization. Drug abuse and alcohol con-
sumption were ruled out; he denied the use of any medi-
cations. Psychiatric evaluation excluded eating disorders.
Physical examination showed feminine appearance charac-
terized by female body fat distribution, high-pitched voice
and eunuchoidal body proportions (height 175 cm, arm
span 177 cm, BMI 27.2 kg/m2). He had minimal body hairs,
mild gynecomastia and elephantiasis for chronic lymph-
edema. Genital examination revealed underdeveloped scro-
tum, microphallus and bilateral cryptorchidism. Gender
dysphoria was absent. Multiple osteoporotic vertebralfractures (T6-T7-T8) were detected by x-ray imaging
study. Hormonal assessment was performed two months
later, after the stabilization of the cardiac condition, con-
firming severe hypogonadotropic hypogonadism [testos-
terone <0.02 ng/mL; follicle-stimulating hormone (FSH)
0.18 mU/mL; luteinizing hormone (LH) <0.1 mU/mL].
Concomitant central hypothyroidism [thyroid-stimulating
hormone (TSH) 7.0 mU/L (n.v. 0.4-4), freeT3 2.1 pg/ml
(n.v. 2.6-4.4), freeT4 0.65 ng/dl (n.v. 0.9-1.7)], growth hor-
mone (GH) deficiency [peak GH of 1.3 ng/ml after com-
bined stimulation with GHRH 1 μg/kg body weight +
arginine 30 g; insulin-like growth factor 1 (IGF1) 25 ng/ml
(n.v. 117–252)] and mild hyperprolactinemia (34 ng/ml;
n.v. < 20) were diagnosed. Pituitary-adrenal axis function
was normal. Pituitary MRI revealed partial empty sella.
Testosterone and L-thyroxine replacement was started; six
months of therapy induced a mild masculinization, weight
gain (+7 kg) and resolution of anemia. Nonetheless, cen-
tral hypothyroidism and GH deficiency did not resolve
(TSH 0.08 mU/L, freeT4 0.83 ng/dl, IGF1 25 ng/ml). The
karyotype was 46XY and genetic screening for mutations
in the hypogonadotropic hypogonadism genes was
negative. In particular, the analysis of the PROKR2 gene
coding sequence, whose allelic variants have recently
been described also in cases of hypopituitarism, was
negative [8-10].
Case 2
A 30 years-old man was admitted to emergency depart-
ment for hypotension, fatigue, anemia and deep bradycar-
dia (32 bpm). He experienced a 19 Kg weight loss in the
last year, once-weekly fainting episodes, progressive diffuse
myalgia and anxious-depressive disorder preventing the
patient to attend minimal daily activity. He was born from
consanguineous parents. He suffered from neurosensorial
hypoacusia consequent to infantile measles meningitis.
Spontaneous puberty occurred at age of 14 years. Since
few months he complained low sexual desire and erectile
dysfunction, while olfactory was normal. Physical examin-
ation revealed BMI 19 kg/m2. On genital examination, tes-
tes were small (volume 5 ml) and soft in the scrotum,
while external genitalia were normal. Cardiac conduction
was investigated: Holter-ECG confirmed severe bradycar-
dia with minimal nocturnal heart rate of 28 bpm; any sig-
nificant pause was recorded. An electrophysiological study
failed to demonstrate conduction abnormality. Echocardi-
ography showed normal cardiac function, absence of con-
genital anomaly; ischemia was ruled out at cardiac stress
test. Malabsorption, alcohol and drug consumption and
eating disorders were excluded. Two months later the
emergency admission, he received an endocrine evaluation
that revealed mild hypothyroidism [TSH 5.5 mU/L, freeT3
1.7 pg/ml (n.v. 2.6-4.4), freeT4 0.8 ng/dl (n.v. 0.9-1.7)], low
IGF1 levels [107 ng/ml (n.v.117-252)], normal adrenal
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gonadism [testosterone 1.3 ng/ml (n.v. 2.4-10.0), LH
0.6 mU/ml, FSH 1.1 mU/ml]. Pituitary MRI was normal.
He promptly started testosterone and L-thyroxine
replacement that induced after six months a dramatic im-
provement of his well-being: the patient experienced a 12
Kg weight gain with improvement of muscle mass and
heart rate (56 bpm). Hypothyroidism resolved, L-thyroxine
was discontinued and IGF1 levels normalized. Genetic
screening for mutations in the candidate genes for
hypogonadotropic hypogonadism, namely FGFR1, PROK2,
PROKR2, GNRH1, GNRH2, was negative.
Discussion
The occurrence of hypogonadism during early adult life,
when testosterone production rate is maximal, has detri-
mental effects to the whole body, including the heart.
Here, we reported two cases experiencing wasting and
deep bradycardia, a life-threatening condition, due to
long-standing severe testosterone deficiency occurring
during their early adulthood. The link between testoster-
one deficiency and cardiac impairment was confirmed as
bradycardia was completely rescued by testosterone re-
placement in the Case 2, though in the Case 1 this infor-
mation was unavailable since a monocameral pace-maker
was implanted before starting testosterone replacement.
In this setting, the two patients did not complain about
sexual dysfunction as general disease state was dominant
in Case 2, while psycho-social reasons blunted this aspect
in Case 1. Lack of sexual complaints helped to fail the
diagnosis of hypogonadism. Testosterone deficiency was
the main finding and hypogonadal features were evident
when appropriately investigated. Typical gonadal-related
features, namely small and soft testis, small size penis, re-
duced body hair did not catch the attention of physicians
during initially evaluation as extra-gonadal features were
prominent. In particular, both patients showed severe re-
duction in skeletal muscle mass and strength, hypoxic
condition due to heart failure, in Case1, and severe anemia
and bradycardia with hypotension, in Case 2.
In both cases, gonadal failure had a pituitary origin
not associated with organic lesions; nonetheless, the
screening for mutations of genes involved in hypogona-
dotrophic hypogonadism was negative.
At the presentation in both patients hypogonadotropic
hypogonadism was associated with low IGF1 and low
freeT4 levels associated with mildly elevated TSH levels.
Thyroid autoimmunity and goiter were absent. On serum
samples, the diagnosis of central hypothyroidism is usually
suggested by the finding of low freeT4 concentrations asso-
ciated with low/normal TSH levels. Nevertheless, some
central hypothyroid patients have high serum immunoreac-
tive TSH levels but are devoid of full biological activity. In
these cases, TSH elevations are similar to those generallyfound in subclinical or mild primary hypothyroidism and
may lead to the misdiagnosis [11]. Nonetheless, differential
diagnosis of central hypothyroidism includes non-thyroidal
illness syndrome, which occurs in the presence of comor-
bidities. Patients with non-thyroidal illness syndrome have
values of thyroid function testing that largely overlap with
those with central hypothyroidism. Considering the out-
comes of the two cases, Case 1 was diagnosed with central
hypothyroidism, while Case 2 findings were consistent with
non-thyroidal illness syndrome due to detrimental hypo-
gonadism. A similar pattern of presentation was observed
for GH secretion. Supporting the pituitary origin of the
hormonal deficiency in Case 1, mild hyperprolactinemia,
usually seen in pituitary defects and secondary to the hypo-
thalamic thyrotropin-releasing hormone (TRH) stimulation,
was detected.
Though the effect of central hypothyroidism on cardiac
presentation could not be ruled out in these patients, the
mild freeT3 reduction and the recovery of euthyroidism in
the Case 2 supported a dominant role of long-standing
gonadic failure rather than hypothyroidism in determining
the clinical presentation. It is worth noting that in the Case
1, GH and TSH deficiencies were likely to become manifest
later than hypogonadism as the patient had been previously
diagnosed with isolated hypogonadotropic hypogonadism
and no growth failure or short stature were detected.
The impact of testosterone on the cardiovascular sys-
tem is controversial. Nonetheless, testosterone seems to
be beneficial to the heart and low levels of testosterone
negatively affect cardiovascular system [3]. Moreover,
testosterone has been shown to exhibit potential antiar-
rhythmic properties in the form of decreasing action po-
tential duration and shortened QTc interval [12] and
low levels of testosterone in obese men have been sug-
gested to contribute to their arrhythmogenic profile [13].Conclusion
Long-standing severe central hypogonadism in males is
here reported to be associated with life-threatening body
alterations including severe bradycardia. We suggested
that unexplained bradycardia or heart failure in an other-
wise healthy heart might require a metabolic-endocrine
screening comprehensive of pituitary function evaluation.Consent
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